GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Cyclically Adjusted PB Ratio

Corcept Therapeutics (Corcept Therapeutics) Cyclically Adjusted PB Ratio : 8.67 (As of Apr. 28, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Corcept Therapeutics's current share price is $22.80. Corcept Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $2.63. Corcept Therapeutics's Cyclically Adjusted PB Ratio for today is 8.67.

The historical rank and industry rank for Corcept Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

CORT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.39   Med: 13.73   Max: 61.22
Current: 8.68

During the past years, Corcept Therapeutics's highest Cyclically Adjusted PB Ratio was 61.22. The lowest was 2.39. And the median was 13.73.

CORT's Cyclically Adjusted PB Ratio is ranked worse than
86.9% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs CORT: 8.68

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Corcept Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was $4.900. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.63 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Corcept Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Corcept Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Cyclically Adjusted PB Ratio Chart

Corcept Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.24 21.51 11.84 9.49 12.36

Corcept Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.49 9.49 9.28 10.81 12.36

Competitive Comparison of Corcept Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Corcept Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Cyclically Adjusted PB Ratio falls into.



Corcept Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Corcept Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=22.80/2.63
=8.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Corcept Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=4.9/129.4194*129.4194
=4.900

Current CPI (Dec. 2023) = 129.4194.

Corcept Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.093 99.695 0.121
201406 0.034 100.560 0.044
201409 -0.013 100.428 -0.017
201412 -0.033 99.070 -0.043
201503 0.098 99.621 0.127
201506 0.106 100.684 0.136
201509 0.124 100.392 0.160
201512 0.169 99.792 0.219
201603 0.184 100.470 0.237
201606 0.232 101.688 0.295
201609 0.282 101.861 0.358
201612 0.367 101.863 0.466
201703 0.438 102.862 0.551
201706 0.583 103.349 0.730
201709 0.756 104.136 0.940
201712 1.665 104.011 2.072
201803 1.868 105.290 2.296
201806 2.098 106.317 2.554
201809 2.248 106.507 2.732
201812 2.398 105.998 2.928
201903 2.486 107.251 3.000
201906 2.623 108.070 3.141
201909 2.930 108.329 3.500
201912 3.240 108.420 3.868
202003 3.573 108.902 4.246
202006 3.926 108.767 4.671
202009 4.215 109.815 4.967
202012 4.483 109.897 5.279
202103 4.385 111.754 5.078
202106 4.513 114.631 5.095
202109 4.685 115.734 5.239
202112 3.547 117.630 3.903
202203 3.839 121.301 4.096
202206 4.147 125.017 4.293
202209 4.397 125.227 4.544
202212 4.654 125.222 4.810
202303 4.896 127.348 4.976
202306 4.113 128.729 4.135
202309 4.482 129.860 4.467
202312 4.900 129.419 4.900

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corcept Therapeutics  (NAS:CORT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Corcept Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics (Corcept Therapeutics) Business Description

Traded in Other Exchanges
Address
149 Commonwealth Drive, Menlo Park, CA, USA, 94025
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Executives
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer officer: Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb officer: CHIEF FINANCIAL OFFICER C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon officer: Chief Accounting Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck officer: See Remarks C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt officer: Chief Scientific Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff director, officer: CHIEF EXECUTIVE OFFICER 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr director, 10 percent owner 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer officer: Chief Medical Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025